Do analysts recommend PTIX or CMND?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Clearmind Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, PTIX or CMND?

Atrinsic is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atrinsic N/A N/A -$5.53M -$3.45 N/A Clearmind Medicine N/A N/A -$3.86M -$139.98 N/A

Is PTIX or CMND more profitable?

Atrinsic's return on equity of 0.00% beat Clearmind Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% Clearmind Medicine N/A -143.79% -88.51%

Do analysts recommend PTIX or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, PTIX or CDT?

Atrinsic is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atrinsic N/A N/A -$5.53M -$3.45 N/A CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A

Is PTIX or CDT more profitable?

Atrinsic's return on equity of 0.00% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% CDT Equity N/A -4,263.33% -529.91%

Do analysts recommend PTIX or BPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, PTIX or BPTH?

Atrinsic is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atrinsic N/A N/A -$5.53M -$3.45 N/A Bio-Path N/A N/A -$16.08M -$1.09 N/A

Is PTIX or BPTH more profitable?

Atrinsic's return on equity of 0.00% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% Bio-Path N/A -2,842.40% -337.48%

Do analysts rate PTIX or SHPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, PTIX or SHPH?

Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atrinsic N/A N/A -$5.53M -$3.45 N/A Shuttle Pharmaceuticals N/A N/A -$11.72M -$47.70 N/A

Is PTIX or SHPH more profitable?

Atrinsic's return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% Shuttle Pharmaceuticals N/A -408.34% -138.15%

Do analysts prefer ORGS or PTIX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ORGS or PTIX more profitable?

Atrinsic has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% Atrinsic N/A N/A -379.72%

Atrinsic (PTIX) Competitors

$0.23 0.00 (0.00%)

As of 07/2/2026 03:59 PM Eastern

Compare

PTIX vs. CMND, CDT, BPTH, SHPH, and ORGS

Should you buy Atrinsic stock or one of its competitors? MarketBeat compares Atrinsic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atrinsic include Clearmind Medicine (CMND), CDT Equity (CDT), Bio-Path (BPTH), Shuttle Pharmaceuticals (SHPH), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical products" industry.

How does Atrinsic compare to Clearmind Medicine?

Atrinsic (NASDAQ:PTIX) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Atrinsic has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

In the previous week, Clearmind Medicine had 2 more articles in the media than Atrinsic. MarketBeat recorded 2 mentions for Clearmind Medicine and 0 mentions for Atrinsic. Clearmind Medicine's average media sentiment score of 0.52 beat Atrinsic's score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company	Overall Sentiment
Atrinsic	Neutral
Clearmind Medicine	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Clearmind Medicine	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

8.0% of Atrinsic shares are held by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are held by institutional investors. 8.0% of Atrinsic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Atrinsic's return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Clearmind Medicine	N/A	-143.79%	-88.51%

Atrinsic is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A
Clearmind Medicine	N/A	N/A	-$3.86M	-$139.98	N/A

Summary

Clearmind Medicine beats Atrinsic on 6 of the 11 factors compared between the two stocks.

How does Atrinsic compare to CDT Equity?

Atrinsic (NASDAQ:PTIX) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Atrinsic's return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
CDT Equity	N/A	-4,263.33%	-529.91%

In the previous week, Atrinsic's average media sentiment score of 0.00 equaled CDT Equity'saverage media sentiment score.

Company	Overall Sentiment
Atrinsic	Neutral
CDT Equity	Neutral

Atrinsic is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A

Atrinsic has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, CDT Equity has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

8.0% of Atrinsic shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 8.0% of Atrinsic shares are held by insiders. Comparatively, 10.8% of CDT Equity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Atrinsic beats CDT Equity on 5 of the 8 factors compared between the two stocks.

How does Atrinsic compare to Bio-Path?

Atrinsic (NASDAQ:PTIX) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

In the previous week, Atrinsic's average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company	Overall Sentiment
Atrinsic	Neutral
Bio-Path	Neutral

Atrinsic is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

8.0% of Atrinsic shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 8.0% of Atrinsic shares are held by company insiders. Comparatively, 0.7% of Bio-Path shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Atrinsic has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.52, suggesting that its share price is 152% less volatile than the broader market.

Atrinsic's return on equity of 0.00% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Bio-Path	N/A	-2,842.40%	-337.48%

Summary

Atrinsic beats Bio-Path on 7 of the 9 factors compared between the two stocks.

How does Atrinsic compare to Shuttle Pharmaceuticals?

Atrinsic (NASDAQ:PTIX) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

In the previous week, Shuttle Pharmaceuticals had 6 more articles in the media than Atrinsic. MarketBeat recorded 6 mentions for Shuttle Pharmaceuticals and 0 mentions for Atrinsic. Shuttle Pharmaceuticals' average media sentiment score of 1.31 beat Atrinsic's score of 0.00 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Atrinsic	Neutral
Shuttle Pharmaceuticals	Positive

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Atrinsic has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Shuttle Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

Atrinsic's return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%

Summary

Atrinsic beats Shuttle Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Atrinsic compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and Atrinsic (NASDAQ:PTIX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Atrinsic'saverage media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
Atrinsic	Neutral

22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 8.0% of Atrinsic shares are owned by institutional investors. 1.9% of Orgenesis shares are owned by insiders. Comparatively, 8.0% of Atrinsic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Atrinsic has lower revenue, but higher earnings than Orgenesis. Atrinsic is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A

Orgenesis has a beta of 3.15, meaning that its share price is 215% more volatile than the broader market. Comparatively, Atrinsic has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Atrinsic has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Atrinsic	N/A	N/A	-379.72%

Summary

Atrinsic beats Orgenesis on 6 of the 10 factors compared between the two stocks.

Get Atrinsic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTIX vs. The Competition

Export

Metric	Atrinsic	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$416K	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.03	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.12	8.66	10.96	6.46
Net Income	-$5.53M	$23.81M	$3.57B	$337.01M
7 Day Performance	-36.09%	3.39%	2.12%	1.69%
1 Month Performance	-54.00%	10.81%	5.25%	3.81%
1 Year Performance	-93.23%	62.61%	33.29%	23.90%

Atrinsic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTIX Atrinsic	N/A	$0.23 flat	N/A	-93.2%	$416K	N/A	N/A	2	Gap Up High Trading Volume
CMND Clearmind Medicine	1.2514 of 5 stars	$2.36 +2.6%	N/A	-99.5%	$2.41M	N/A	N/A	N/A
CDT CDT Equity	0.6101 of 5 stars	$0.49 -5.7%	N/A	-99.9%	$2.40M	N/A	N/A	3	Gap Up
BPTH Bio-Path	N/A	$0.05 +34.3%	N/A	-72.5%	$2.36M	N/A	N/A	10	Gap Down
SHPH Shuttle Pharmaceuticals	1.6545 of 5 stars	$3.65 +7.4%	N/A	-90.9%	$2.34M	N/A	N/A	5	News Coverage Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTIX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atrinsic (PTIX) Competitors

PTIX vs. CMND, CDT, BPTH, SHPH, and ORGS

How does Atrinsic compare to Clearmind Medicine?

Summary

How does Atrinsic compare to CDT Equity?

Summary

How does Atrinsic compare to Bio-Path?

Summary

How does Atrinsic compare to Shuttle Pharmaceuticals?

Summary

How does Atrinsic compare to Orgenesis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTIX vs. The Competition

Atrinsic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atrinsic (PTIX) Competitors

PTIX vs. CMND, CDT, BPTH, SHPH, and ORGS

How does Atrinsic compare to Clearmind Medicine?

Which has more volatility and risk, PTIX or CMND?

Does the media prefer PTIX or CMND?

Do analysts recommend PTIX or CMND?

Do insiders and institutionals believe in PTIX or CMND?

Is PTIX or CMND more profitable?

Which has higher earnings and valuation, PTIX or CMND?

Summary

How does Atrinsic compare to CDT Equity?

Do analysts recommend PTIX or CDT?

Is PTIX or CDT more profitable?

Does the media refer more to PTIX or CDT?

Which has preferable earnings & valuation, PTIX or CDT?

Which has more risk and volatility, PTIX or CDT?

Do institutionals and insiders have more ownership in PTIX or CDT?

Summary

How does Atrinsic compare to Bio-Path?

Does the media refer more to PTIX or BPTH?

Which has stronger valuation & earnings, PTIX or BPTH?

Do analysts recommend PTIX or BPTH?

Do insiders and institutionals have more ownership in PTIX or BPTH?

Which has more volatility and risk, PTIX or BPTH?

Is PTIX or BPTH more profitable?

Summary

How does Atrinsic compare to Shuttle Pharmaceuticals?

Does the media refer more to PTIX or SHPH?

Do insiders & institutionals believe in PTIX or SHPH?

Which has stronger earnings & valuation, PTIX or SHPH?

Do analysts rate PTIX or SHPH?

Which has more volatility and risk, PTIX or SHPH?

Is PTIX or SHPH more profitable?

Summary

How does Atrinsic compare to Orgenesis?

Does the media favor ORGS or PTIX?

Do institutionals & insiders have more ownership in ORGS or PTIX?

Which has preferable earnings & valuation, ORGS or PTIX?

Which has more risk & volatility, ORGS or PTIX?

Do analysts prefer ORGS or PTIX?

Is ORGS or PTIX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTIX vs. The Competition

Atrinsic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools